Patient considerations in the use of tapentadol for moderate to severe pain

Medicine & Life Sciences

• Tapentadol 100%
• Pain 34%
• Opioid Analgesics 26%
• Oxycodone 13%
• Acute Pain 10%
• United States Food and Drug Administration 9%
• Tablets 9%
• Chronic Pain 9%
• Norepinephrine 8%
• Central Nervous System Depressants 7%
• Non-Narcotic Analgesics 7%
• Clinical Trials 6%
• Drug Approval 6%
• Monoamine Oxidase Inhibitors 6%
• mu Opioid Receptor 5%
• Diabetic Neuropathies 5%
• Illicit Drugs 5%
• Anti-Anxiety Agents 5%
• Liver Failure 5%
• Sleepiness 5%
• Dizziness 5%
• Postoperative Pain 5%
• Hypnotics and Sedatives 5%
• Respiratory Insufficiency 4%
• Antipsychotic Agents 4%
• Nausea 4%
• Renal Insufficiency 4%
• Vomiting 4%
• Analgesics 4%
• Cognitive Dysfunction 4%
• Quality of Life 3%
• Muscles 3%
• Morbidity 2%
• Therapeutics 1%

Social Sciences

• pain 57%
• Clinical Trials 20%
• cognitive impairment 12%
• morbidity 10%
• quality of life 7%
• disability 6%
• drug 6%